Advertisement

Picture [iito] No Tracking 650x80px
Organisation › Details

Deutsche Biotech Innovativ AG (DBI AG)

Deutsche Biotech Innovativ AG (“DBI”) is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapeutic solutions for serious illnesses for which no adequate medical solutions have yet been found. The focus of the R&D is on drugs for sepsis and cancer. The company’s main product is the patented drug Adrecizumab for decreasing mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a Phase I study starting in 2015. The preclinical and clinical studies are mainly carried out by project companies in which the DBI AG is involved. Currently, the DBI AG holds 26 percent of AdrenoMed AG, 25 percent of Oncoprevent GmbH, 50 percent of My Life Diagnostics GmbH and 100 percent of AngioBiomed GmbH. DBI aims to further expand its drug pipeline and invests in the research and development of drugs that possess a high unique selling point potential. The members of the DBI Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have long-standing experience in the biotechnology field. Both were part of the founders‘ and management team of B.R.A.H.M.S. AG, a very successful biotechnology company specializing in the determination of blood biomarker levels for treating serious illnesses, which was sold in 2009 for around EUR 330 million. Dr. Bernd Wegener is a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie). *

 

Period Start 2014-10-21 renamed
  Group Deutsche Biotech Innovativ (Group)
  Predecessor Venetus Beteiligungen AG
Products Industry venture capital
  Industry 2 BIOTECH
Persons Person Wegener, Bernd (Deutsche Biotech Innovativ AG before BRAHMS CEO)
  Person 2 Bergmann, Andreas (Sphingotec GmbH 201301 Managing Director)
     
Region Region Hennigsdorf
  Country Germany
  Street 15A Neuendorfstr.
  City 16761 Hennigsdorf
  Tel +49-3302-2077811
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Deutsche Biotech Innovativ AG. (8/6/15). "Press Release: Sepsis Drug Adrecizumab Shows High Degree of Efficacy in Preclinical Studies". Hennigsdorf.
     
   
Record changed: 2017-04-01

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Deutsche Biotech Innovativ (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top